Zübeyde EMİRALİOĞLU ÇAKIR, Hakan GÖLBAŞI, Burak BAYRAKTAR, Selviye HALKSEVER ÖZVATAN, Raziye TORUN, İlayda GERCİK ARZIK, Hale ANKARA AKTAŞ, Emre BAYRAM, Selcan KESAN, Altuğ KOÇ, Atalay EKİN
Forbes Tıp Dergisi - 2026;7(1):23-32
Objective: To evaluate contemporary indications, diagnostic yield, diagnostic limitations, and pregnancy-neonatal outcomes of chorionic villus sampling (CVS) in a tertiary referral population in the era of widespread non-invasive prenatal testing. Methods: This retrospective cohort study included 70 singleton pregnancies that underwent CVS at a tertiary referral center between October 2023 and June 2025. Maternal characteristics, indications for CVS, genetic testing results, and procedure-related outcomes were recorded. Pregnancy loss, the need for repeat invasive testing, termination decisions, and delivery and neonatal outcomes were assessed. Results: Major fetal structural anomalies were the leading indication (40%). Pathological genetic findings were identified in 21.4% of cases. Despite multimodal testing, 5.7% remained without a result, and 17.1% required repeat invasive sampling. No immediate complications occurred. Four pregnancy losses before 24 weeks' gestation (5.7%) were observed. Three occurred in pregnancies with major structural or chromosomal abnormalities, while one occurred in a structurally normal fetus with inconclusive cytogenetic results. When anomaly-associated cases were excluded, the observed loss rate among structurally normal pregnancies was 1.4%. No membrane rupture or chorioamnionitis occurred. Among live births, 97.2% were delivered at term. Neonatal outcomes were reassuring, and stillbirths (3.1%) were attributable to severe fetal or maternal pathology rather than the CVS procedure. Conclusion: Structural fetal anomalies are now the leading indication for CVS. Post-procedure complications were rare, and most adverse outcomes were observed in pregnancies with underlying fetal or maternal pathology. These findings support the continued role of CVS as a diagnostic option in selected high-risk pregnancies.
